StreetInsider.com News Articles

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:52:00 -0400

si-local-file:///var/storage/secattach/20260708/26744368.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:52:00 -0400

si-local-file:///var/storage/secattach/20260708/26744368.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: VAN HEEK G JAN

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612444.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: VAN HEEK G JAN

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612444.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Kaul Inderjit

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612445.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Kaul Inderjit

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612445.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Kupfer David

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612448.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Kupfer David

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612448.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: HASLER HANS PETER

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612449.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: HASLER HANS PETER

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612449.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Laghrissi-Thode Fouzia

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612451.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Laghrissi-Thode Fouzia

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612451.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Ahlholm Frederick W

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612452.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Ahlholm Frederick W

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612452.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Luthringer Remy

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612453.html

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Luthringer Remy

Fri, 05 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26612453.html

Form 8-K Minerva Neurosciences, For: Jun 03

Thu, 04 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260604/26605595.html

Form 8-K Minerva Neurosciences, For: Jun 03

Thu, 04 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260604/26605595.html

Minerva Neurosciences forms scientific advisory board

Mon, 01 Jun 2026 16:05:28 -0400

Minerva Neurosciences Inc. (NASDAQ: NERV) announced the establishment of a Scientific Advisory Board to guide the development of its experimental drug roluperidone and broader research strategy, according to a company statement.

The board includes eight members with expertise in psychiatry and neuroscience, including company executives and external researchers from institutions such as the University of Miami, King's College London, and the University of Arkansas for Medical Sciences.

The advisory board will provide guidance on the company's ongoing Phase 3 confirmatory trial of roluperidone for treating negative symptoms of schizophrenia. The global trial, designated NCT07565428, plans to enroll approximately 380 adults aged 18-55

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Mon, 01 Jun 2026 16:05:00 -0400

Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy

BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Company’s PIPE financing announced on October 21, 2025. The SAB brings together distinguished researchers and clinicians with proven track records of advancing meaningful treatments in psychiatry and neuroscience.

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Mon, 01 Jun 2026 16:05:00 -0400

Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy

Form 8-K Minerva Neurosciences, For: May 27

Wed, 27 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26558148.html

Form 8-K Minerva Neurosciences, For: May 27

Wed, 27 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26558148.html

Form 424B5 Minerva Neurosciences,

Wed, 27 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26558053.html

Form 424B5 Minerva Neurosciences,

Wed, 27 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26558053.html